

CC animals.
XX
SQ Sequence 605 AA;

Query Match 100.0%; Score 315; DB 19; Length 605;
Best Local Similarity 100.0%; Pred. No. 2.3e-26;
Matches 55; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ENPKHNKCLQSCNSERDSTRNQACHARNLTKYKECEGEIIPRPRPQHPER 55
:|||||
Db 31 enpkhnkclqscnsersdstrnqacharnltkvekecegeiprprpqhper 85

RESULT 2

Y40999 ID Y40999 standard; protein; 605 AA.
XX
AC Y40999;

DT 06-DEC-1999 (first entry)
XX

DE Soybean beta-conglycinin protein sequence.
XX

KM Peanut; allergen; Ara H 1; IgE; immunoglobulin E; epitope: Ara h 3;
KW allergic reaction; soybean; beta-conglycinin.
XX

OS Glycine max.
XX

PN MO9945961-A1.
XX

PD 16-SEP-1999.
XX

PF 12-MAR-1999; 99WO-US05494.
XX

PR 12-MAR-1998; 98US-0077763.
XX

PR 11-MAR-1999; 99US-0077763.
XX

PA (UYAR-) UNIV ARKANSAS.
XX

PI Burks W, Helm RM, Cockrell G, Bannon GA, Stanley JS, Shin DS;
PI Sampson H, Compadre CM, Huang SK, Maleki SJ, Kopper RA;
XX

DR WPI; 1999-551218/46.
XX

PT Tertiary structure of peanut allergen Ara h 1 for protection of a host
PT animal from allergic reaction -
XX

PS Disclosure: Fig 33A-B; 193pp; English.
XX

CC The invention provides a tertiary structure for the peanut allergen
CC Ara H 1. The Ara H 1 allergen is found to contain 23 linear IgE-binding
CC epitopes. The invention also provides an isolated recombinant peanut
CC allergen designated Ara h 3 and a nucleotide molecule encoding the peanut
CC allergen Ara h 3. Molecules of the invention are used to protect a host
CC animal from allergic reaction, particularly using a modified allergen
CC which is less reactive with IgE. The invention may also be used to
CC ensure that the allergen is not introduced into genetically modified
CC food. The present sequence represents a soybean beta-conglycinin protein
CC sequence.
XX

SQ Sequence 605 AA;

Query Match 96.2%; Score 303; DB 20; Length 605;
Best Local Similarity 94.5%; Pred. No. 4.4e-25;
Matches 52; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 ENPKHNKCLQSCNSERDSTRNQACHARNLTKYKECEGEIIPRPRPQHPER 55
:|||||
Db 31 knpkhnkclqscnsersdstrnqacharnltkvekecegeiprprpqhper 85

RESULT 3

W22149 ID W22149 standard; protein; 614 AA.
XX

AC W22149;
XX

DT 29-DEC-1997 (first entry)
XX

DE Peanut allergen Ara h1.
XX

KM Peanut; seed storage protein; allergen; allergy; hypersensitivity;
KW vaccine; anaphylactic shock; immunotherapy; therapy;
KW monoclonal antibody; ELISA; analysis; Ara h1.
XX

OS Arachis hypogaea strain Florunner.
XX

FH Key Location/Qualifiers
FT Peptide 1..22
FT Protein /label= Sig-peptide
FT FT 23..614
FT FT /label= Mat_protein
FT FT 521..523
FT FT /note= "N-glycosylation site"

PN MO9724139-A1.
XX

PD 10-JUL-1997.
XX

PF 23-SEP-1996; 96WO-US15222.
XX

PR 04-MAR-1996; 96US-0610424.
XX

PR 29-DEC-1995; 95US-0009455.
XX

PA (UYAR-) UNIV ARKANSAS.
XX

PI Bannon GA, Burks AW, Cockrell G, Helm RM, Stanley JS;
PI WPI; 1997-363453/33.
XX

DR N-PSDB; T76612.
XX

PT Peanut allergens Ara h1 and Ara h1t - used for vaccination and in
PT two-site monoclonal antibody based ELISA
XX

PS Claim 31; Page 169; 354pp; English.
XX

CC This polypeptide comprises major peanut allergen Ara h1 (W22149).
CC Its sequence was deduced from cDNA clone P17 (T76612), isolated
CC from peanut seed cDNA using a primer (see T76616) based on an
CC isolated Ara h1 peptide (see W24206). The sequence shows
CC significant homology with the vicilin family of seed storage
CC proteins of other legumes. The allergen is recognised by serum
CC IgE from a large proportion of individuals with peanut
CC hypersensitivity. Ara h1 and Ara h1t (see W24164) can be used to
CC raise monoclonal antibodies which are used in a specific two-site
CC MAb ELISA for the detection of Ara h1 or Ara h1t (claimed). IgE-
CC binding Ara h1 antigen epitopes (see W24165-87) may be used in
CC vaccines to protect against allergic reactions to peanut allergens,
CC e.g. anaphylactic shock.
XX

SQ Sequence 614 AA;

Query Match 28.3%; Score 89; DB 18; Length 614;
Best Local Similarity 44.1%; Pred. No. 0.049;
Matches 15; Conservative 6; Mismatches 13; Indels 0; Gaps 0;

QY 1 ENPKHNKCLQSCNSERDSTRNQACHARNLTKYKECEGEIIPRPRPQHPER 34
:|||||
Db 33 empcaqrclqscsqgqepddlkqkacsrckleyd 66

RESULT 4
W62834

```

ID 10-MAR-1997.
XX 23-SEP-1996; 96WO-US15222.
XX 04-MAR-1996; 96US-0610424.
XX 29-DEC-1995; 95US-0009455.
XX (UYAR-) UNIV ARKANSAS.
XX Bannon GA, Burks AW, Cockrell G, Helm RM, Stanley JS;
XX WPI, 1997-363453/33.
XX N-PSDB; T76613.
XX Peanut allergens Ara hi and Ara hii - used for vaccination and in
XX two-site monoclonal antibody based ELISA
XX Claim 31, Page 172; 354pp; English.
XX
XX This polypeptide comprises major peanut allergen Ara hi (W22149).
XX Its sequence was deduced from cDNA clone P41b (T76613), isolated
XX from peanut seed cDNA using a primer (see T76616) based on an
XX isolated Ara hi peptide (see W24206). The sequence shows
XX significant homology with the vicilin family of seed storage
XX proteins of other legumes. The allergen is recognised by serum
XX IgE from a large proportion of individuals with peanut
XX hypersensitivity. Ara hi and Ara hii (see W24164) can be used to
XX raise monoclonal antibodies which are used in a specific two-site
XX MAb ELISA for the detection of Ara hi or Ara hii (claimed). IgE-
XX binding Ara hi antigen epitopes (see W24165-87) may be used in
XX CC vaccines to protect against allergic reactions to peanut allergens,
XX e.g. anaphylactic shock.
XX
SQ Sequence 614 AA:

Query Match 28.3%; Score 89; DB 19; Length 614;
Best Local Similarity 44.1%; Pred. No. 0.049;
Matches 15; Conservative 6; Mismatches 13; Indels 0; Gaps 0;

OY 1 ENPKHMKCLOSCNERSRYSRNOACHARNLKV 34
   ||| :||||| | : ||| || | :
Db 33 enpcagrcldqscgqepddlkqkacesrcrkleyd 66

RESULT 5
W22150 ID W22150 standard; Protein; 626 AA.
XX
AC W22150;
XX
DT 29-DEC-1997 (first entry)
XX
DE Peanut allergen Ara hi.
XX
XX Peanut; seed storage protein; allergen; allergy; hypersensitivity;
XX vaccine; anaphylactic shock; immunotherapy; therapy;
XX monoclonal antibody; ELISA; analysis; Ara hi.
XX
OS Arachis hypogaea strain Florunner.
XX
FH Key Location/Qualifiers
FT Peptide 1..22 /label= Sig_peptide
FT Protein 23..626 /label= Mat_protein
FT Modified-site 521..523 /note= "N-glycosylation site"
XX
XX W09724139-A1.

```

```

PD 10-JUL-1997.
XX
XX 23-SEP-1996; 96WO-US15222.
XX 04-MAR-1996; 96US-0610424.
XX 29-DEC-1995; 95US-0009455.
XX (UYAR-) UNIV ARKANSAS.
XX Bannon GA, Burks AW, Cockrell G, Helm RM, Stanley JS;
XX WPI, 1997-363453/33.
XX N-PSDB; T76613.
XX Peanut allergens Ara hi and Ara hii - used for vaccination and in
XX two-site monoclonal antibody based ELISA
XX Claim 31, Page 172; 354pp; English.
XX
XX This polypeptide comprises major peanut allergen Ara hi (W22149).
XX Its sequence was deduced from cDNA clone P41b (T76613), isolated
XX from peanut seed cDNA using a primer (see T76616) based on an
XX isolated Ara hi peptide (see W24206). The sequence shows
XX significant homology with the vicilin family of seed storage
XX proteins of other legumes. The allergen is recognised by serum
XX IgE from a large proportion of individuals with peanut
XX hypersensitivity. Ara hi and Ara hii (see W24164) can be used to
XX raise monoclonal antibodies which are used in a specific two-site
XX MAb ELISA for the detection of Ara hi or Ara hii (claimed). IgE-
XX binding Ara hi antigen epitopes (see W24165-87) may be used in
XX CC vaccines to protect against allergic reactions to peanut allergens,
XX e.g. anaphylactic shock.
XX
SQ Sequence 626 AA:

Query Match 28.3%; Score 89; DB 18; Length 626;
Best Local Similarity 44.1%; Pred. No. 0.05;
Matches 15; Conservative 6; Mismatches 13; Indels 0; Gaps 0;

OY 1 ENPKHMKCLOSCNERSRYSRNOACHARNLKV 34
   ||| :||||| | : ||| || | :
Db 35 enpcagrcldqscgqepddlkqkacesrcrkleyd 68

RESULT 6
Y15244 ID Y15244 standard; Protein; 626 AA.
XX
AC Y15244;
XX
DT 09-NOV-1999 (first entry)
XX
DE Peanut allergen, Ara h 1, amino acid sequence.
XX
XX Allergy; immune response; transgenic; allergen; epitope;
XX immunoglobulin E; Ig E; binding site; peanut.
XX
OS Arachis hypogaea.
XX
XX W0938978-A1.
XX
XX 05-AUG-1999.
XX
PD 29-JAN-1999; 99WO-US02031.
XX
XX 27-AUG-1998; 98US-0141220.
XX 31-JAN-1998; 98US-0073283.
XX 13-FEB-1998; 98US-0074590.
XX 13-FEB-1998; 98US-0074624.
XX 13-FEB-1998; 98US-0074633.
XX
XX (SOSI/) SOSIN H.

```


	has selective inhibitory activity for factor VIIa/TF. The specification describes a method for screening an isolated protein at least one domain for factor VIIa/TF selective inhibitory activity. The method comprises determining the time to clotting effected by a concentration of the isolated protein in an ex vivo prothrombin time (PT) assay and an ex vivo activated partial thromboplastin time (APTT) assay; calculating prolongation of clotting effected by the isolated protein in each of the PT and APTT assay, with respect to a baseline clotting value for each assay, where prolongation of clotting is calculated as fold elevation of clotting time relative to a baseline clotting value, where a doubling of clotting time is deemed a two-fold elevation; and calculating a PR to APTT prolongation ratio, where a ratio at least one is indicative of factor VIIa/TF inhibitory activity. The method is useful for determining if a protein has factor VIIa/TF inhibitory activity.
SQ	Sequence 78 AA:
XX	
Dc	Query Match 21.3%; Score 67; DB 20; Length 78;
Oy	Best Local Similarity 29.7%; Pred. No. 1.4;
Dd	Matches 19; Conservative 9; Mismatches 20; Indels 16; Gaps 3;
Oy	5 HNKCLSGNSERSDYRNQACHAR-----CN--LTK-----VEKERCEGELPRRP 48 :: : :
Dd	15 Ykqgerkmckelsekdeacslactgracycnqjyrdffgnvcevkdecndmelitfpp 74 : ! : ! :
Oy	49 RPOH 52
Dd	75 elkh 78
RESULT 9	
V30436 ID	Y30436 standard; Protein; 162 AA.
XX AC	Y30436:
XX DT	15-NOV-1999 (first entry)
DE XX	Mature nematode extracted anticoagulant protein AcANAP45.
KW KM	Nematode extracted anticoagulant protein; NAF; anticoagulant; Serine protease inhibitor; NAP domain; factor VIIa/TF.
OS XX	Ancylostoma caninum.
PX XX	US5955294-A.
XX PD	21-SEP-1999.
XX PF	19-APR-1996; 96US-0634641.
XX PR	19-APR-1996; 96US-0634641.
PR	18-OCT-1994; 94US-0326110.
PR	05-JUN-1995; 95US-0461965.
PR	05-JUN-1995; 95US-046380.
PR	05-JUN-1995; 95US-046397.
PR	05-JUN-1995; 95US-046399.
PR	17-OCT-1995; 95WO-US13231.
PA PA	(CORV-) CORVAS INT INC.
PI PI	Bergum PW, Gansemans YGJ, Jespers LS, Iarchoe YR;
PI PI	Lauwereys MJ, Messens JHL, Moyle M, Stanssens PEH;
PI PI	Vlasuk GP;
XX DR	WPI: 1999-539569/45.
XX PT	Screening an isolated protein for Nematode-extracted Anticoagulant Protein domains
XX PS	Disclosure; Fig 18; 197pp; English

```

XX  The present sequence represents a nematode extracted anticoagulant
CC  protein (NAP). The protein has activity as an anticoagulant and/or serine
CC  protease inhibitor. The protein contains at least one NAP domain which
CC  has selective inhibitory activity for factor VIIa/TF. The specification
CC  describes a method for screening an isolated protein at least one domain
CC  for factor VIIa/TF selective inhibitory activity. The method comprises
CC  determining the time to clotting effected by a concentration of the
CC  isolated protein in an ex vivo prothrombin time (PT) assay and an ex vivo
CC  activated partial thromboplastin time (APTT) assay; calculating
CC  prolongation of clotting effected by the isolated protein in each of
CC  the PT and APTT assay, with respect to a baseline clotting value for
CC  each assay, where prolongation of clotting is calculated as fold
CC  elevation of clotting time relative to a baseline clotting value, where
CC  a doubling of clotting time is deemed a two-fold elevation; and
CC  calculating a PT to APTT prolongation ratio, where a ratio at least
CC  one is indicative of factor VIIa/TF inhibitory activity. The method is
CC  useful for determining if a protein has factor VIIa/TF inhibitory
CC  activity.
XX
XX  Sequence 162 AA:
XX
XX
XX
XX
XX  Query Match 21.3%; Score 67; DB 20; Length 162;
XX  Best Local Similarity 29.7%; Fred. No. 2.9;
XX  Matches 19; Conservative 9; Mismatches 20; Indels 16; Gaps 3;
XX
XX  5 HNKLCQSCNSERDSYRNQACHAR-----CN--LTK-----VEKPERCEGEIIPRP 48
XX  Db 99 ykgerckckhsekddeacisractgacvengdllyrdldfgncvckedcndmelitfpp 158
XX  Qy 49 RPDH 52
XX  :|
XX  Db 159 eckh 162
XX
XX  RESULT 10
XX  ID R91711 standard; Protein: 181 AA.
XX
XX  AC R91711:
XX
XX  17-NOV-1996 (first entry)
XX
XX  DE AcanAP45.
XX
XX  KW ACcNAP; HPCcNAP; MamcNAP; AcenAP; AdunAP; anticoagulant;
XX  KW nematode-extracted anticoagulant protein; serine protease;
XX  KW nematode; thrombostis; parasitic worm.
XX
XX  OS Ancylostoma caninum.
XX
XX  PN W09612021-A2.
XX
XX  PD 25-APR-1996.
XX
XX  PF 17-OCT-1995; 95WO-US13231.
XX
XX  PR 05-JUN-1995; 95US-0486399.
XX  PR 18-OCT-1994; 94US-0326110.
XX  PR 05-JUN-1995; 95US-0461965.
XX  PR 05-JUN-1995; 95US-0465380.
XX  PR 05-JUN-1995; 95US-0486397.
XX
XX  PA (CORV-) CORVAS INT INC.
XX
XX  Bergum PW, Gensemans YGJ, Jespers LS, Laroche YR;
XX  Lauweys MJ, Messens JH, Moyle M, Stanssens PH;
XX  Vlasuk GP.
XX  WPI: 1996-222007/22.
XX  PR N-PSDB; 112957.
XX

```



```

PR      18-OCT-1994;       94US-0326110.
PR      05-JUN-1995;       95US-0461965.
PR      05-JUN-1995;       95US-0465380.
PR      05-JUN-1995;       95US-0463387.
PR      05-JUN-1995;       95US-0463397.
PR      05-JUN-1995;       95US-0466399.
PR      17-OCT-1995;       95WO-US13231.
XX
PA      (CORV-) CORVAS INT INC.
XX
PI      Bergum PW, Gansemaans YGJ, Jespers LS, Laroche YR;
PI      Lauwereys MJ, Messens JHL, Moyle M, Stanssens PEH;
PI      Vlasuk GP.
XX
XX      WPI: 1999-539569/45.
DR
PT      Screening an isolated protein for Nematode-extracted Anticoagulant
PT      Protein domains
XX
PS      Disclosure; Columns 139-140; 197pp; English.
XX
CC      The present sequence represents a nematode extracted anticoagulant
CC      protein (NAP). The protein has activity as an anticoagulant and/or serine
CC      protease inhibitor. The protein contains at least one NAP domain which
CC      has selective inhibitory activity for factor VIIa/TF. The specification
CC      describes a method for screening an isolated protein at least one domain
CC      for factor VIIa/TF selective inhibitory activity. The method comprises
CC      determining the time to clotting effected by a concentration of the
CC      isolated protein in an ex vivo prothrombin time (PT) assay and an ex vivo
CC      activated partial thromboplastin time (APTT) assay; calculating
CC      prolongation of clotting effected by the isolated protein in each of
CC      the PT and APTT assay, with respect to a baseline clotting value for
CC      each assay, where prolongation of clotting is calculated as fold
CC      elevation of clotting time relative to a baseline clotting value, where
CC      a doubling of clotting time is deemed a two-fold elevation; and
CC      calculating a PR to APTT prolongation ratio, where a ratio at least
CC      one is indicative of factor VIIa/TF inhibitory activity. The method is
CC      useful for determining if a protein has factor VIIa/TF inhibitory
CC      activity.
XX
SQ      Sequence      78 AA:
XX
Query Match          20.3%; Score 64; DB 20; Length 78;
Best Local Similarity 28.1%, Pred. No. 2.9;
Matches 18; Conservative 10; Mismatches 20; Indels 16; Gaps 3;
QY      5 HNKGLDSNSERDYSRNQACHAR-----CN--LTK-----VEKERCEGETIPRRP 48
        ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db      15 ykgerkkseejsekneacslractgracycngdyrdgfnecvkecdnmetiltpp 74
QY      49 RPOH 52
        :|
Db      75 etkh 78
DE      RESULT 13
ID      Y30437
XX      Y30437 standard; Protein; 162 AA.
AC      Y30437;
XX
DT      15-NOV-1999 (first entry)
XX
DE      Mature nematode extracted anticoagulant protein AcANAP47.
KW      Nematode extracted anticoagulant protein; NAP; anticoagulant;
KW      serine protease inhibitor; NAP domain; factor VIIa/TF.
OS      Ancylostoma caninum.
XX
PN      US5955294-A.
XX
DD      21-SEP-1999.
```

PF	19-APR-1996;	96US-0634641.
XX	19-APR-1996;	96US-0634641.
PR	18-OCT-1994;	94US-0326110.
PR	05-JUN-1995;	95US-0461965.
PR	05-JUN-1995;	95US-0465380.
PR	05-JUN-1995;	95US-0486397.
PR	05-JUN-1995;	95US-0486399.
PR	17-OCT-1995;	95WO-0513231.
PA	(CORV-) CORVAS INT INC.	
PI	Bergum PW, Gansemaans YGJ, Jespers LS, Laroche YR;	
PI	Launereys MJ, Messens JHL, Moyle M, Stanssens PEH;	
PI	Vlasuk GP;	
DR	WPI: 1999-539569/45.	
XX		
PT	Screening an isolated protein for Nematode-extracted Anticoagulant	
PT	Protein domains	
XX		
PS	Disclosure: Fig 19; 197pp; English.	
XX		
CC	The present sequence represents a nematode extracted anticoagulant	
CC	protein (NAP). The protein has activity as an anticoagulant and/or serine	
CC	protease inhibitor. The protein contains at least one NAP domain which	
CC	has selective inhibitory activity for factor VIIa/TF. The specification	
CC	describes a method for screening an isolated protein at least one domain	
CC	for factor VIIa/TF selective inhibitory activity. The method comprises	
CC	determining the time to clotting effected by a concentration of the	
CC	isolated protein in an ex vivo prothrombin time (PT) assay and an ex vivo	
CC	activated partial thromboplastin time (APTT) assay; calculating	
CC	prolongation of clotting effected by the isolated protein in each of	
CC	the PT and APTT assay, with respect to a baseline clotting value for	
CC	each assay, where prolongation of clotting is calculated as fold	
CC	elevation of clotting time relative to a baseline clotting value, where	
CC	a doubling of clotting time is deemed a two-fold elevation; and	
CC	calculating a PT to APTT prolongation ratio, where a ratio at least	
CC	one is indicative of factor VIIa/TF inhibitory activity. The method is	
CC	useful for determining if a protein has factor VIIa/TF inhibitory	
CC	activity.	
XX		
SQ	Sequence 162 AA;	
XX		
Query Match	20.3%: Score 64; DB 20; Length 162;	
Best Local Similarity	28.1%: Pred. No. 6.1;	
Matches 18; Conservative 10; Mismatches 20; Indels 16; Gaps 3;		
QY	5 HNKLCQSCNSERDYSRNOACHAR-----CN--LLK-----VEKECEGECEIPRRP 48	
Db	99 ykqcrkscseelsekneacslsractgracvcdngldyrdffgncvckecndmeitltp 158	
QY	49 RPOH 52	
Db	159 etkh 162	
RESULT 14		
R91712	R91712 standard; Protein; 181 AA.	
XX		
AC	R91712;	
XX		
DT	17-NOV-1996 (first entry)	
XX		
DE	AcANAP47.	
XX		
ACANAP:	hPONAP: NamNAP: AcenAP: AdunAP: anticoagulant;	
KW	nematode-extracted anticoagulant protein; serine protease;	
KW	nematode; thrombosis; parasitic worm.	
XX		

```

OS Ancylostoma caninum.
XX
XX W09612021-A2.
XX
XX 25-APR-1996.
XX
XX 17-OCT-1995; 95WO-US13231.
XX
XX 05-JUN-1995; 95US-0486399.
XX
XX 18-OCT-1994; 94US-0326110.
XX
XX 05-JUN-1995; 95US-0461965.
XX
XX 05-JUN-1995; 95US-0465380.
XX
XX 05-JUN-1995; 95US-0486397.
XX
XX (CORV-) CORVAS INT INC.
XX
XX Bergum PM, Gansemans YGJ, Jespers LS, Laroche YR;
XX Lauwerijs MJ, Messens JHL, Moyle M, Stanssens PEH;
XX Vlaesk GP;
XX
XX WPI: 1996-222007/22.
XX
XX N-PSDB: T12958.
XX
XX Proteins with anticoagulant and/or serine protease inhibitory
XX activity - isolated from nematodes and useful to inhibit blood
XX coagulation
XX
XX Clalm 221; Fig 136; 243pp; English.
XX
XX Proteins with anticoagulant and/or serine protease inhibitory
XX activity, isolated from nematodes, are useful to inhibit blood
XX coagulation. The proteins can be added to blood collection tubes
XX defining the collection of mammalian plasma. They are also useful
XX to prevent or inhibit thrombosis, and may be given alone or in
XX combination with other therapeutic or in vivo diagnostic agents.
XX The proteins can serve as immunogens to raise antibodies for use in
XX the diagnosis and identification of NMP concn. levels in biological
XX fluids, e.g. to detect mammalian infection with a parasitic worm.
XX They can also be used as immunogens in prophylactic and therapeutic
XX vaccines against parasitic worm infection. The proteins may
XX double the clotting time of human plasma in prothrombin time assays
XX when present at 10-50 nmol, and double the clotting time of human
XX plasma in activated partial thrombin time assays when present
XX at 10-100 nmol.
XX
XX The anticoagulant proteins are pref. derived from
XX Ancylostoma caninum, A. ceylanicum, A. duodenale, Necator
XX americanus or Heligmosomoides polygyrus.
XX The proteins pref. have 2 NMP domains and specifically inhibit
XX the catalytic activity of the factor VIIa/TF complex in the
XX presence of factor Xa or a catalytically inactive factor Xa deriv.,
XX do not specifically inhibit the activation of factor VIIa in the
XX absence of TF and do not specifically inhibit prothrombinase.
XX
XX Sequence 181 AA:
SQ
Query Match 20.3%; Score 64; DB 17; Length 181;
Best Local Similarity 28.1%; Pred. No. 6.9;
Matches 18; Conservative 10; Mismatches 20; Indels 16; Gaps 3;
OY 5 HMKCLOSCNSERSTYRNOACHAR-----CN--LLK-----VKKECEEGEIRPRP 48
DB 118 ykqckckseelsekneacistractgracvncdgyrdldfgncvkecdndmelltfpp 177
OY 49 RPOH 52
DB 178 etkh 181
RESULT 15
Y30410
ID Y30410 standard; protein: 181 AA.
XX

```

```

AC Y30410;
XX
XX 15-NOV-1999 (first entry)
XX
XX Nematode extracted anticoagulant protein AcanAP45.
XX
XX Nematode extracted anticoagulant protein; NMP; anticoagulant;
XX serine protease inhibitor; NMP domain; factor VIIa/TF.
XX
XX Ancylostoma caninum.
XX
XX US95955294-A.
XX
XX 21-SEP-1999.
XX
XX 19-APR-1996; 96US-0634641.
XX
XX 19-APR-1996; 96US-0634641.
XX
XX 18-OCT-1994; 94US-0326110.
XX
XX 05-JUN-1995; 95US-0461965.
XX
XX 05-JUN-1995; 95US-0465380.
XX
XX 05-JUN-1995; 95US-0486397.
XX
XX 05-JUN-1995; 95US-0486399.
XX
XX 17-OCT-1995; 95WO-US13231.
XX
XX (CORV-) CORVAS INT INC.
XX
XX Bergum PM, Gansemans YGJ, Jespers LS, Laroche YR;
XX Lauwerijs MJ, Messens JHL, Moyle M, Stanssens PEH;
XX Vlaesk GP;
XX
XX WPI: 1999-539569/45.
XX
XX N-PSDB: Z10458.
XX
XX Screening an isolated protein for Nematode-extracted Anticoagulant
XX Protein domains
XX
XX Example 12; Fig 136; 197pp; English.
XX
XX The present sequence represents a nematode extracted anticoagulant
XX protein (NMP). The protein has activity as an anticoagulant and/or serine
XX protease inhibitor. The protein contains at least one NMP domain which
XX describes a method for screening an isolated protein at least one domain
XX for factor VIIa/TF selective inhibitory activity. The method comprises
XX determining the time to clotting effected by a concentration of the
XX isolated protein in an ex vivo prothrombin time (PT) assay and an ex vivo
XX activated partial thromboplastin time (APTT) assay; calculating
XX prolongation of clotting effected by the isolated protein in each of
XX the PT and APTT assay, with respect to a baseline clotting value for
XX each assay, where prolongation of clotting is calculated as fold
XX elevation of clotting time relative to a baseline clotting value, where
XX a doubling of clotting time is deemed a two-fold elevation; and
XX calculating a PT to APTT prolongation ratio, where a ratio at least
XX one is indicative of factor VIIa/TF inhibitory activity. The method is
XX useful for determining if a protein has factor VIIa/TF inhibitory
XX activity.
XX
XX Sequence 181 AA:
SQ
Query Match 20.3%; Score 64; DB 20; Length 181;
Best Local Similarity 28.1%; Pred. No. 6.9;
Matches 18; Conservative 10; Mismatches 20; Indels 16; Gaps 3;
OY 5 HMKCLOSCNSERSTYRNOACHAR-----CN--LLK-----VKKECEEGEIRPRP 48
DB 118 ykqckckseelsekneacistractgracvncdgyrdldfgncvkecdndmelltfpp 177
OY 49 RPOH 52
DB 178 etkh 181

```


Search completed: March 1, 2001, 16:09:37
Job time: 1329 sec
